Good thing Bristol-Myers' Opdivo and Eliquis surged in Q1. Its other drugs didn'tadmin 26th April 2018 Uncategorised 0
Bristol-Myers Squibb may face questions about how its immuno-oncology treatment Opdivo will compete with Merck & Co.’s Keytruda in lung cancer‚ but meanwhile, the drug’s bringing home the bacon. Its $1.5 billion in sales—plus a strong showing from clot-busting Eliquis—made the company’s first quarter look decent.
More: Good thing Bristol-Myers' Opdivo and Eliquis surged in Q1. Its other drugs didn't